• 手机改美国ip地址
  • Important Safety Information
  • Prescribing Information
  • 苹果手机改国外ip

LINZESS (linaclotide) is indicated in adults for the treatment of both irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).1

Different patients.
Multiple symptoms. The #1 Prescribed Branded IBS-C Treatment*

*IQVIA Monthly Total Prescriptions Volume data as of February 2024.
Data are subject to change.

Overall Abdominal Symptoms DataThe effect of LINZESS on overall abdominal symptoms, including bloating, discomfort, and pain.2

免费试用加速器-ios加速器

手机修改ip为美国加速软件

手机网络节点怎么换国外

免费试用加速器-ios加速器

  • LINZESS is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
  • LINZESS is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

免费试用加速器-ios加速器

Pediatric Risk

  • LINZESS is contraindicated in patients less than 6 years of age. The safety and effectiveness of LINZESS in patients less than 18 years of age have not been established. In neonatal mice, linaclotide increased fluid secretion as a consequence of GC-C agonism resulting in mortality within the first 24 hours due to dehydration. Due to increased intestinal expression of GC-C, patients less than 6 years of age may be more likely than patients 6 years of age and older to develop severe diarrhea and its potentially serious consequences.
  • Use of LINZESS should be avoided in pediatric patients 6 years to less than 18 years of age. Although there were no deaths in older juvenile mice, given the deaths in young juvenile mice and the lack of clinical safety and efficacy data in pediatric patients, use of LINZESS should be avoided in pediatric patients 6 years to less than 18 years of age.

Diarrhea

  • Diarrhea was the most common adverse reaction in LINZESS-treated patients in the pooled IBS-C and CIC double-blind placebo-controlled trials. The incidence of diarrhea was similar in the IBS-C and CIC populations. Severe diarrhea was reported in 2% of 145 mcg and 290 mcg LINZESS-treated patients, and in <1% of 72 mcg LINZESS-treated CIC patients. If severe diarrhea occurs, dosing should be suspended and the patient rehydrated.

Common Adverse Reactions (incidence ≥2% and greater than placebo)

  • In IBS-C clinical trials: diarrhea (20% vs 3% placebo), abdominal pain (7% vs 5%), flatulence (4% vs 2%), headache (4% vs 3%), viral gastroenteritis (3% vs 1%) and abdominal distension (2% vs 1%).
  • In CIC trials of a 145 mcg dose: diarrhea (16% vs 5% placebo), abdominal pain (7% vs 6%), flatulence (6% vs 5%), upper respiratory tract infection (5% vs 4%), sinusitis (3% vs 2%) and abdominal distension (3% vs 2%). In a CIC trial of a 72 mcg dose: diarrhea (19% vs 7% placebo) and abdominal distension (2% vs <1%).
LINZESS® (linaclotide) is indicated in adults for the treatment of both irritable bowel syndrome with constipation (IBS‑C) and chronic idiopathic constipation (CIC).
If you are a patient, and have any questions, please discuss them with your doctor or healthcare professional. For additional information about LINZESS, call Allergan Medical Information at 1.800.678.1605.
Please see below and full Prescribing Information for LINZESS.

免费试用加速器-ios加速器

More
 

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS

LINZESS is contraindicated in patients less than 6 years of age. In nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration. Use of LINZESS should be avoided in patients 6 years to less than 18 years of age. The safety and effectiveness of LINZESS have not been established in patients less than 18 years of age.

免费试用加速器-ios加速器

  • LINZESS is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
  • LINZESS is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

免费试用加速器-ios加速器

Pediatric Risk

  • 苹果(iOS)软件下载_手机下载_太平洋下载中心:2021-9-6 · 太平洋手机下载中心提供免费手机软件下载。包括苹果(iOS)软件下载、苹果(iOS)游戏下载。海量苹果(iOS)软件游戏，高速安全下载。 “POCO相机“是 ...
  • Use of LINZESS should be avoided in pediatric patients 6 years to less than 18 years of age. Although there were no deaths in older juvenile mice, given the deaths in young juvenile mice and the lack of clinical safety and efficacy data in pediatric patients, use of LINZESS should be avoided in pediatric patients 6 years to less than 18 years of age.

Diarrhea

  • Diarrhea was the most common adverse reaction in LINZESS-treated patients in the pooled IBS-C and CIC double-blind placebo-controlled trials. The incidence of diarrhea was similar in the IBS-C and CIC populations. Severe diarrhea was reported in 2% of 145 mcg and 290 mcg LINZESS-treated patients, and in <1% of 72 mcg LINZESS-treated CIC patients. If severe diarrhea occurs, dosing should be suspended and the patient rehydrated.

Common Adverse Reactions (incidence ≥2% and greater than placebo)

  • In IBS-C clinical trials: diarrhea (20% vs 3% placebo), abdominal pain (7% vs 5%), flatulence (4% vs 2%), headache (4% vs 3%), viral gastroenteritis (3% vs 1%) and abdominal distension (2% vs 1%).
  • In CIC trials of a 145 mcg dose: diarrhea (16% vs 5% placebo), abdominal pain (7% vs 6%), flatulence (6% vs 5%), upper respiratory tract infection (5% vs 4%), sinusitis (3% vs 2%) and abdominal distension (3% vs 2%). In a CIC trial of a 72 mcg dose: diarrhea (19% vs 7% placebo) and abdominal distension (2% vs <1%).
LINZESS® (linaclotide) is indicated in adults for the treatment of both irritable bowel syndrome with constipation (IBS‑C) and chronic idiopathic constipation (CIC).
芝麻伕理IP软件 - 千万稳定动态IP切换，IP伕理覆盖全国:2021-6-6 · 芝麻伕理ip软件是国内专业的ip伕理服务器提供商，提供http伕理，API接口和自动换IP伕理软件，千万高匿名ip覆盖全国随意切换，支持PC、iOS、安卓，高效稳定免费试用，国内ip伕理软件、http伕理 …
Please see below and full Prescribing Information for LINZESS.
猎豹vp加速器官网,猎豹加速器官网入口,猎豹加速器签到送一小时,  蚂蚁vp加速器官网,蚂蚁加速器官网下载,蚂蚁vqn下载官网,  十大免费加速神器,每天赠送一小时加速器,签到送时长加速器,每天试用一小时vp加速器猎豹  坚果加速器ios下载,坚果加速器vnp,坚果加速器vpm,坚果加速器vn  飞兔加速器官网网址,飞兔加速器电脑版下载,飞兔加速器mac下载,飞兔加速器vps  暴雪加速器,暴雪vp加速器官网,暴风加速器正版官网,  快鸭vp加速器,小黄鸭加速器,快鸭加速器官网,